The Technical Analyst
Benitec Biopharma Inc [BNTC]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Benitec Biopharma Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.83% $4.78
America/New_York / 16 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 12.39 mill |
| EPS: | -236.13 |
| P/E: | -0.0200 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 2.59 mill |
| Avg Daily Volume: | 0.0182 mill |
| RATING 2024-04-16 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | ||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0200 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.00x |
| Company: PE -0.0200 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.751 (-84.28%) $-4.03 |
| Date: 2024-04-16 |
| Expected Trading Range (DAY) |
|---|
|
$ 4.44 - 5.13 ( +/- 7.22%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-06 | Banks Jerel A. | Buy | 466 554 | Options (right to buy) |
| 2024-03-06 | Boston Megan | Buy | 200 004 | Options (right to buy) |
| 2023-12-06 | Smith Edward F | Buy | 35 000 | Options (right to buy) |
| 2023-12-06 | Francis Peter | Buy | 35 000 | Options (right to buy) |
| 2023-12-06 | Buchi J Kevin | Buy | 35 000 | Options (right to buy) |
| INSIDER POWER |
|---|
| 100.00 |
| Last 38 transactions |
| Buy: 2 361 696 | Sell: 57 465 |
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $4.78
Forecast 2: 16:00 - $4.78
Forecast 3: 16:00 - $4.78
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $4.78 (-0.83% ) |
| Volume | 0.0270 mill |
| Avg. Vol. | 0.0182 mill |
| % of Avg. Vol | 148.46 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For BNTC
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
BNTC
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
Latest Press Releases
2024-02-13 08:00:00 - Press Release
Benitec Biopharma Releases Second Quarter 2024 Financial Results And Provides Operational Update
-first subject dosed with bb-301 in phase 1b/2a clinical treatment study (nct06185673) in november 2023- -data safety monitoring board review for first subject completed after day 28 study visit- -second subject scheduled to receive bb-301 in february 2024- -23 subjects enrolled into the oculopharyngeal muscular dystrophy natural history study with multiple subjects eligible for entry into the phase 1b/2a clinical treatment study in 2024- hayward, calif., feb. 13, 2024 (globe newswire) -- benitec biopharma inc. (nasdaq: bntc) (“benitec” or “company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “silence and replace” dna-directed rna interference (“ddrnai”) platform, today announced financial results for its second fiscal quarter ended december 31, 2023.
2023-11-30 07:00:00 - Press Release
Benitec Biopharma Announces First Subject Dosed In Phase 1b/2a Clinical Trial For Gene Therapy Candidate Bb-301 For The Treatment Of Oculopharyngeal Muscular Dystrophy
Announcement marks the initiation of the first clinical trial conducted in human subjects employing benitec's “silence and replace” dna-directed rna interference gene therapy platform announcement marks the initiation of the first clinical trial conducted in human subjects employing benitec's “silence and replace” dna-directed rna interference gene therapy platform
2023-11-17 08:00:00 - Press Release
Benitec Biopharma To Participate In A Fireside Chat At The 35th Annual Piper Sandler Healthcare Conference
Hayward, calif., nov. 17, 2023 (globe newswire) -- benitec biopharma inc. (nasdaq: bntc) (“benitec” or “company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary dna-directed rna interference (“ddrnai”) platform, today announced that jerel a. banks, m.d., ph.d., executive chairman and chief executive officer of benitec, will participate in a fireside chat at the 35th annual piper sandler healthcare conference on thursday, november 30th, 2023 at 10:00 am et.
2023-11-13 08:00:00 - Press Release
Benitec Biopharma Releases First Quarter 2024 Financial Results And Provides Operational Update
Hayward, calif., nov. 13, 2023 (globe newswire) -- benitec biopharma inc. (nasdaq: bntc) (“benitec” or “company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary dna-directed rna interference (“ddrnai”) platform, today announced financial results for its first fiscal quarter ended september 30, 2023.
2023-09-21 08:00:00 - Press Release
Benitec Biopharma Releases Full Year 2023 Financial Results And Provides Operational Update
Received fda clearance of the investigational new drug (ind) application for bb-301 for the treatment of oculopharyngeal muscular dystrophy (opmd)-related dysphagia
Latest News
2023-05-08 08:05:00 - GlobeNewsWire
Benitec Biopharma to Present at the OPMD International Conference
HAYWARD, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced that Jerel A.
2022-06-24 11:21:57 - PennyStocks
Penny Stocks To Buy Now? 4 Biotech Stocks To Watch Before July 2022
2021-09-13 15:58:00 - PRNewsWire
Benitec Biopharma to present at H.C. Wainwright's 23rd Annual Global Investment Conference
HAYWARD, Calif., Sept. 13, 2021 /PRNewswire/ -- Benitec Biopharma, Inc. (NASDAQ: BNTC), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced that Jerel A.
2021-09-08 08:10:00 - PRNewsWire
Benitec Biopharma Provides Overview of the BB-301 Phase 1b/2a Clinical Trial Design for 2022
HAYWARD, Calif., Sept. 8, 2021 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC), a development-stage biotechnology company focused on the advancement of novel genetic medicines, today provided an overview of the key elements of the BB-301 Phase 1b/2a clinical trial design.
2021-09-08 08:05:00 - PRNewsWire
Benitec Biopharma Provides Positive Updates on the BB-301 Pilot Dosing Study in Large Animals
HAYWARD, Calif., Sept. 8, 2021 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC), a development-stage biotechnology company focused on the advancement of novel genetic medicines, today provided an update on the ongoing analyses of the large animal subjects treated with BB-301 in the Pilot Dosing Study.
2021-04-27 21:55:00 - PRNewsWire
Benitec Biopharma Increases Previously Announced Bought Deal Offering of Common Stock to $12.9 Million
HAYWARD, Calif., April 27, 2021 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced that, due to demand, the underwriter has agreed to increase the size of the previously announced offering and purchase on a firm commitment basis 3,036,366 shares of common stock of the Company at a price to the public of $4.25 per share, less underwriting discounts and commissions.
2021-04-27 16:44:00 - PRNewsWire
Benitec Biopharma Announces $7.5 Million Bought Deal Offering of Common Stock
HAYWARD, Calif., April 27, 2021 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced that it has entered into an underwriting agreement with H.C.
2021-03-23 22:20:14 - Pulse2
BNTC Stock Price Increased 190.28%: Why It Happened
The stock price of Benitec Biopharma Inc (NASDAQ: BNTC) increased by 190.28% today. This is why it happened.
2021-03-23 17:03:02 - Benzinga
Benitec BioPharma Shares Rally: Technical Levels To Watch
Benitec BioPharma Inc. (NASDAQ: BNTC) shares rallied Tuesday following a filing by Morgan Stanley that showed the bank increased its stake in the Australian biotechnology company by 5.2%. The stock gained 190.28% in Tuesday's session, closing at $9.26, and was giving back 11.12% to $8.23 in after-hours trading at last check.
2021-03-23 09:57:33 - InvestorPlace
What Will the Stock Market Do Today? 3 Big Stories to Watch.
What will the stock market do today? All eyes are on President Joe Biden and his spending plan, as well as Covid-19 vaccine news.